FDA Approves Cefepime-Zidebactam Injection - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA Approves Cefepime-Zidebactam Injection

Phase 3 ENHANCE-1 results showed higher composite clinical cure and microbiologic response rates with cefepime-zidebactam vs meropenem in hospitalized adults with complicated urinary tract infection or acute pyelonephritis.

  • By

  • Kathryn Wighton

  • June 3, 2026

  • 2 min

Share

  • 1

    The FDA approved cefepime and zidebactam for treating complicated urinary tract infections in adults.

  • 2

    The approval is based on the phase 3 ENHANCE-1 trial, which involved 530 patients across multiple countries.

  • 3

    Cefepime and zidebactam achieved a composite clinical cure rate of 89%, compared to 68% for meropenem.

  • 4

    The treatment combines a fourth-generation cephalosporin with a non-beta-lactam antibacterial and beta-lactamase inhibitor.

  • 5

    Cefepime and zidebactam received Priority Review, Fast Track, and Qualified Infectious Disease Product designations from the FDA.

Original Source(s)

FDA Approves Cefepime-Zidebactam Injection

  • by Kathryn Wighton

  • June 3, 2026

Related Content

Mesenchymal stem cell - derived extracellular vesicles modulate immune function in sepsis

Same-Day COVID, Flu Vaccination Appears Safe

Study found no increased 90-day risk of serious adverse events with coadministration compared with vaccination alone.

Top 10 CDC Updates Physicians Should Know

Recent CDC advisories, testing updates, and immunization recommendations highlight developments in infectious diseases, immunization, and diagnostic testing relevant to physicians across multiple specialties.